Catheter Precision, Inc.
For the period ended Mar 31, 2026. Filed May 18, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 18, 2026
VTAK$0.15-0.7%Stored close · as of Oct 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(1,690) | $(4,045) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 405 | 531 |
| Stock-based compensation | 64 | 91 |
| Amortization of operating right-of-use assets | 97 | 23 |
| Change in fair value of minority equity interest | 2,302 | — |
| Change in fair value of deferred consideration | (2,877) | — |
| Change in fair value of royalties payable due to related parties | — | 1,163 |
| Deferred income tax provision (benefit) | (174) | (724) |
| Acquired in-process research and development | — | 119 |
| Accretion of discount on note payable | 28 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (105) | (16) |
| Inventories | 19 | (43) |
| Prepaid expenses and other current assets | (349) | 68 |
| Operating lease right-of-use assets and lease liabilities | (97) | (25) |
| Current portion of royalties payable due to related parties | (42) | (11) |
| Accounts payable | (514) | 410 |
| Accrued expenses | 119 | 76 |
| Deferred revenue | (45) | — |
| Interest payable due to related parties | 48 | 45 |
| Interest accrued on notes payable of variable interest entities | 15 | — |
| Net cash used in operating activities | (2,796) | (2,338) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Consideration paid for acquired in-process research and development | (103) | — |
| Purchases of property and equipment | (6) | (10) |
| Acquisition, net of cash acquired | (1,210) | — |
| Net cash used in investing activities | (1,319) | (10) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock and equity-classified contracts, net of issuance costs | 3,731 | — |
| Proceeds from exercise of warrants (see Note 12) | 401 | — |
| Payments on short-term notes payable | (499) | (75) |
| Proceeds from notes payable | 835 | — |
| Net cash provided by (used in) financing activities | 4,468 | (75) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 353 | (2,423) |
| CASH AND CASH EQUIVALENTS, beginning of period. | 88 | 2,873 |
| CASH AND CASH EQUIVALENTS, end of period. | $441 | $450 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | $21 | $4 |
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES | ||
| Deemed dividend on warrant inducement offer | $1,360 | $— |
| Fair value of common stock issued in connection with asset acquisitions | $— | $113 |
| Fair value of deferred consideration payable for initial minority equity interest | $5,250 | $— |
| Acquisition date fair value of previously held minority equity interest of step acquiree | $2,948 | $— |
| Fair value of deferred consideration payable in connection with acquisition | $5,778 | $— |
| Short-term note payable issued in connection with acquisition | $4,788 | $— |
| Property and equipment included in accrued expenses | $— | $7 |
| Property and equipment reclassified from inventories | $5 | $5 |
| Operating right-of-use asset obtained in exchange for new operating lease liabilities | $584 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.